Publicaciones (25) Publicaciones de Alejandro Gallego Martínez

2024

  1. Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer?

    Cancers, Vol. 16, Núm. 2

  2. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

2023

  1. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526

  2. Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  3. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  4. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models

    Frontiers in Oncology, Vol. 12

  2. Dostarlimab for the treatment of advanced endometrial cancer

    Expert Review of Clinical Pharmacology, Vol. 15, Núm. 1, pp. 1-9

  3. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

  4. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

    Cancers, Vol. 14, Núm. 4

  5. Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer

    Modern Pathology, Vol. 35, Núm. 2, pp. 256-265

  6. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer

    International Journal of Gynecological Cancer, Vol. 32, Núm. 8, pp. 1009-1016

  7. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

2021

  1. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  2. Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study

    Journal of Cancer Survivorship, Vol. 15, Núm. 6, pp. 811-817

  3. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma

    Virchows Archiv, Vol. 479, Núm. 6, pp. 1167-1176

  4. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience

    Clinical and Translational Oncology, Vol. 23, Núm. 6, pp. 1245-1252

  5. Long-term response to olaparib in BRCA1 -related ovarian cancer with brain metastases

    International Journal of Gynecological Cancer, Vol. 31, Núm. 9, pp. 1292-1296

2020

  1. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1849-1856

2019

  1. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma

    Cancers, Vol. 11, Núm. 12